Business
Zai Lab Highlights Strategic Priorities and Global Pipeline Progress at 44th Annual J.P. Morgan Healthcare Conference
SHANGHAI & CAMBRIDGE, Mass., January 13, 2026--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today provided an update on the Company’s 2026 strategic priorities and clinical development progress. These updates will be discussed as part of the Company’s presentation at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026, at 3:00 p.m. PT / 6:00 p.m. ET.
About this update from Jp Morgan Chase & Co.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":217,"url":"https://media.zenfs.com/en/business-wire.com/ee9104fd60d66495880cad0aa89bfa63"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/QWlhBlg_.cikUJ153NynMQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQzNDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/ee9104fd60d66495880cad0aa89bfa63","width":480,"height":217}},"lazy":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":224,"url":"https://media.zenfs.com/en/business-wire.com/0780f544286f763208fa78e956b72510"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/JyHQZthmm4oLcWxYRjjhSQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ0ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/0780f544286f763208fa78e956b72510","width":480,"height":224}}},{"type":"text","content":"- Zocilurtatug pelitecan (Zoci) positioned to become Zai Lab’s first global oncology launch, with three registration-enabling studies across 2L+ SCLC, 1L SCLC and NEC by the end of 2026","length":185,"tagName":"p","attribs":{}},{"type":"text","content":"- Rapidly advancing a differentiated global pipeline, including ZL-1503 (IL-13xIL-31), ZL-6201 (LRRC15 ADC), ZL-1222 (PD-1xIL-12) and ZL-1311 (MUC17xCD3)","length":153,"tagName":"p","attribs":{}},{"type":"text","content":"- COBENFY approved in China, with commercial launch expected in 1H 2026","length":71,"tagName":"p","attribs":{}},{"type":"text","content":"- Zai Lab to present at the J.P. Morgan Annual Healthcare Conference on Tuesday, January 13, 2026, at 3:00 p.m. PT / 6:00 p.m. ET","length":129,"tagName":"p","attribs":{}},{"type":"text","content":"SHANGHAI & CAMBRIDGE, Mass., January 13, 2026--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today provided an update on the Company’s 2026 strategic priorities and clinical development progress. These updates will be discussed as part of the Company’s presentation at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026, at 3:00 p.m. PT / 6:00 p.m. ET.","length":415,"tagName":"p"},{"type":"text","content":""Since our founding, we have intentionally built Zai Lab as a dual-engine company ...